Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)

被引：41
|
作者：
Puzanov, Igor
Callahan, Margaret K.
Linette, Gerald P.
Patel, Sapna Pradyuman
Luke, Jason J.
Sosman, Jeffrey Alan
Wolchok, Jedd D.
Hamid, Omid
Minor, David R.
Orford, Keith W.
Hug, Bruce A.
Ma, Bo
Matthys, Gemma M.
Hoos, Axel
机构：
[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Angeles Clin & Res Inst, Los Angeles, CA USA
[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA
[8] GlaxoSmithKline, Res & Dev, Collegeville, PA USA
[9] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2511
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
    Ouellet, Daniele
    Kassir, Nastya
    Chiu, Joannellyn
    Mouksassi, Mohamad-Samer
    Leonowens, Cathrine
    Cox, Donna
    DeMarini, Douglas J.
    Gardner, Olivia
    Crist, Wendy
    Patel, Kiran
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 807 - 817
  • [22] Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.
    Corcoran, Ryan Bruce
    Atreya, Chloe Evelyn
    Falchook, Gerald Steven
    Infante, Jeffrey R.
    Hamid, Omid
    Messersmith, Wells A.
    Daud, Adil
    Kwak, Eunice Lee
    Ryan, David
    Kurzrock, Razelle
    Sun, Peng
    Cunningham, Elizabeth Ann
    Orford, Keith W.
    Motwani, Monica
    Bai, Yuchen
    Patel, Kiran
    Venook, Alan P.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma
    Hauschild, A.
    Santinami, M.
    Long, G. V.
    Atkinson, V.
    Mandala, M.
    Sileni, V. Chiarion
    Nyakas, M. S.
    Dutriaux, C.
    Haydon, A.
    Robert, C.
    Mortier, L.
    Schachter, J.
    Ji, R.
    Zhang, P.
    Mookerjee, B.
    Legos, J.
    Kefford, R.
    Dummer, R.
    Kirkwood, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
    Long, G. V.
    Flaherty, K. T.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Chiarion-Sileni, V.
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    Davies, M. A.
    Lane, S. R.
    Legos, J. J.
    Mookerjee, B.
    Grob, J. -J.
    ANNALS OF ONCOLOGY, 2017, 28 (07) : 1631 - 1639
  • [25] Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D plus T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).
    Flaherty, Keith
    Daud, Adil
    Weber, Jeffrey S.
    Sosman, Jeffrey Alan
    Kim, Kevin
    Gonzalez, Rene
    Hamid, Omid
    Infante, Jeffrey R.
    Cebon, Jonathan S.
    Schuchter, Lynn Mara
    Long, Georgina V.
    Algazi, Alain Patrick
    Kudchadkar, Ragini Reiney
    Puzanov, Igor
    Lawrence, Donald P.
    Kline, Amy S.
    Cunningham, Elizabeth Ann
    Sun, Peng
    Patel, Kiran
    Kefford, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
    Yasutomo Teshima
    Minako Kizaki
    Ryohei Kurihara
    Ryosuke Kano
    Miki Harumiya
    International Journal of Clinical Oncology, 2020, 25 : 1870 - 1878
  • [27] Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
    Teshima, Yasutomo
    Kizaki, Minako
    Kurihara, Ryohei
    Kano, Ryosuke
    Harumiya, Miki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (10) : 1870 - 1878
  • [28] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
    Robert, C.
    Karaszewska, B.
    Schachter, J.
    Rutkowski, P.
    Mackiewicz, A.
    Stroyakovskiy, D.
    Lichinitser, M.
    Dummer, R.
    Grange, F.
    Mortier, L.
    Chiarion-Sileni, V.
    Drucis, K.
    Krajsova, I.
    Hauschild, A.
    Mookerjee, B.
    Legos, J.
    Schadendorf, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S664
  • [29] Exposure-Response Analysis of the Effect of Trametinib, a MEK inhibitor, on Tumor Size in Patients with V600 BRAF Mutation Positive Melanoma
    Chiu, Joannellyn
    Ouellet, Daniele
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S115 - S115
  • [30] Phase 2 study of neoadjuvant dabrafenib plus trametinib (D plus T) for resectable stage iib/c BRAF-V600 mutation positive melanoma.
    Saw, Robyn
    Menzies, Alexander M.
    Guminski, Alexander
    Nieweg, Omgo E.
    Shannon, Kerwin F.
    Gonzalez, Maria
    Ch'ng, Sydney
    Kefford, Richard
    Thompson, John F.
    Stretch, Jonathan
    Spillane, Andrew J.
    Scolyert, Richard A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345